Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease
Shih‐Chieh Shao, Kai‐Cheng Chang, Swu‐Jane Lin, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 23

Showing 23 citing articles:

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 53
Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
Jia-Chian Hu, Shih‐Chieh Shao, Daniel Hsiang-Te Tsai, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e240946-e240946
Open Access | Times Cited: 13
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan
Yu‐Chen Su, Jia‐Horung Hung, Kai‐Cheng Chang, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2232584-e2232584
Open Access | Times Cited: 35
Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. 1147-1153
Open Access | Times Cited: 34
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
Jayoung Lim, In‐Chang Hwang, Hong‐Mi Choi, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0269414-e0269414
Open Access | Times Cited: 15
Positive Predictive Value of ICD-10-CM Codes for Myocarditis in Claims Data: A Multi-Institutional Study in Taiwan
Li-Ying Wu, Shih‐Chieh Shao, Shu‐Chen Liao
Clinical Epidemiology (2023) Vol. Volume 15, pp. 459-468
Open Access | Times Cited: 9
Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients
Chuanqiang Wang, Yiteng Qin, Xiaojun Zhang, et al.
Disease Markers (2022) Vol. 2022, pp. 1-7
Open Access | Times Cited: 8
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors among patients with heart failure with preserved ejection fraction
Munaza Riaz, Steven M. Smith, Eric Dietrich, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2023) Vol. 43, Iss. 10, pp. 1024-1031
Closed Access | Times Cited: 4
The association between SGLT2 inhibitors and new-onset acute coronary syndrome in the elderly: a population-based longitudinal cohort study
Tsung-Kun Lin, Mei-Chun Lee, Yu-Han Cheng, et al.
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 4
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study
Xinyi Gao, Nan Zhang, Lei Lü, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 10, Iss. 2, pp. 103-117
Open Access | Times Cited: 4
Validation of Diagnostic Codes to Identify Glaucoma in Taiwan’s Claims Data: A Multi-Institutional Study
Pei-Ting Lu, Tsung‐Hsien Tsai, Chi‐Chun Lai, et al.
Clinical Epidemiology (2024) Vol. Volume 16, pp. 227-234
Open Access | Times Cited: 1
Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis
Hon Jen Wong, Norman Lin, Yao Neng Teo, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 3, pp. 371-383
Closed Access | Times Cited: 1
The influence of SGLT-2 inhibitors on lipid profiles in heart failure patients: a systematic review and meta-analysis
Seyed Mohammad Mahdi Meybodi, Mohammad Amin Karimi, Kourosh Mousazadeh, et al.
American Journal of Cardiovascular Disease (2024) Vol. 14, Iss. 6, pp. 295-305
Closed Access | Times Cited: 1
Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials
Fei Wang, Chunyu Li, Lili Cui, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 1
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
Ai‐Yu Yang, Hung‐Chun Chen
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 6
Preventive Effect Observation of Dapagliflozin on Middle and Later Ventricular Remodeling in Patients with Acute ST Segment Elevation Anterior Wall Myocardial Infarction: A Single-Center, Retrospective Cohort Study
Zeyan Liu, Lijun Liu, Hao Zhang, et al.
Journal of Healthcare Engineering (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 4
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: A Chinese population-based cohort study
Xinyi Gao, Nan Zhang, Lei Lü, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
The impact of SGLT-2 Inhibitors on Lipid Profiles in Heart Failure Patients: a systematic review and meta-analysis
Seyed Mohammadmahdi Meybodi, Mohammad Amin Karimi, Kourosh Mousazadeh, et al.
Research Square (Research Square) (2024)
Open Access
Peran SGLT2i terhadap Risiko Kardiorenal Pasien dengan atau Tanpa Diabetes Melitus Tipe 2
Allen
Cermin Dunia Kedokteran (2024) Vol. 51, Iss. 2, pp. 110-114
Open Access
Mekanisme Penghambat Sodium-Glukosa Transport Protein-2 (SGLT2-i) pada Penyakit Kardiovaskular: Sebuah Tinjauan
Benazier Marcella Besmaya, Sidhi Laksono
MPI (Media Pharmaceutica Indonesiana) (2023) Vol. 5, Iss. 1, pp. 71-85
Open Access | Times Cited: 1
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes
Jayoung Lim, In‐Chang Hwang, Hong‐Mi Choi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 2
Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
Irina Claudia Anton, Liliana Mititelu-Tarţău, T. Popa, et al.
Healthcare (2022) Vol. 10, Iss. 7, pp. 1153-1153
Open Access | Times Cited: 1
Are Sodium-Glucose Cotransporter–2 (SGLT2) Inhibitors related to falls in cardiometabolic patients? An European Pharmacovigilance Analysis
Annamaria Mascolo, Concetta Rafaniello, Donatella Ruggiero, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top